The Altascientist

Altasciences

Science EN ↓ Odcinki: 6

As an end-to-end CRO/CDMO, we have expert knowledge in all early stages of drug development, and we’re sharing that knowledge with you in The Altascientist: The Audiobook. Each issue is a deep dive into a specific area of early-phase drug development, providing insider tips, considerations, and case studies. Altasciences is a drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.

Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: altasciences.com

Autor

The Altascientist

Kategoria

Science

Strona podcastu

altasciences.com

Ostatni odcinek

10 paź 2025

Gdzie słuchać?

Podcasty w aplikacji Replaio Radio Już wkrótce

Podcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów

Pobierz z Google Play Zainstaluj za darmo Android 5 mln+ pobrań · ocena 4,8 iOS niedługo

Odcinki

Issue 46 — Spray-Dried Dispersions 10.10.2025

In this issue, we examine spray-dried dispersions (SDDs) as an effective method to improve solubility and bioavailability of your active pharmaceutical ingredient (API) in early-phase drug development. We review the spray drying process, which converts a liquid into a dry powder, and how the resulting SDDs benefit from improved characteristics for further development. We also discuss the combinati...

Issue 45 — Discovery Studies: An Agile Approach to Early Data for Quicker Decisions 10.10.2025

In this issue, we explore the characteristics and advantages of non-GLP discovery studies, along with emerging trends in this important early phase of drug development research. We also present two case studies from our Sacramento site, highlighting discovery studies that assessed the biodistribution of the test article under specific experimental conditions.

Issue 44 — The Importance of Cytokine Release Assays to Derisk the Development of Immunomodulatory Drugs 10.10.2025

In this issue of The Altascientist, we review strategies, including those implemented at Altasciences, for developing, qualifying, and implementing CRAs to assess the safety of test articles in vitro to complement in vivo preclinical safety assessment.

Issue 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics 08.04.2025

According to the World Health Organization, at least a billion people are currently living with vision impairment from a preventable or treatable source. The main conditions causing their distance vision impairment or blindness are cataracts, refractive error, age-related macular degeneration, glaucoma, diabetic retinopathy, and presbyopia. Precedence Research reports that the global ophthalmic dr...

Issue 42 — Managing the Complexities of Glucagon -like Peptide-1 Receptor Agonist Drug Development 15.11.2024

Current and future development of glucagon-like peptide-1 receptor agonists, more commonly referred to as GLP-1 RAs, or simply as GLP-1s, involves complexities not only in formulation but in all areas of early-phase drug development. Developing and refining preclinical models for early efficacy signals, developing and validating the bioanalytical assays necessary for quantitation, and designing th...

Issue 41 — Immunomodulation Assessments for Clinical Trials 20.09.2024

Immunomodulatory drug development is trending toward increasingly complex modalities as science advances and more effective and safe immunotherapies are needed. Immunomodulatory drugs are at the forefront for the treatment of various types of cancer, infectious diseases, and numerous autoimmune diseases, including rheumatoid arthritis, type I diabetes, lupus, and multiple sclerosis. As the complex...

Słuchaj podcastu Altasciences w Replaio

Radio i podcasty w jednej aplikacji - za darmo, bez zakładania konta. Zainstaluj już dziś i nie przegap premiery

Pobierz z Google Play

Replaio nie jest wydawcą podcastów; nazwy audycji, okładki i audio należą do ich autorów i są rozpowszechniane przez publiczne kanały RSS